

# Bibliography

- Hansen, A. R., Graham, D. M., Pond, G. R., and Siu, L. L. (2014). Phase 1 trial design: is 3+ 3 the best? *Cancer Control*, 21(3):200–208.
- Jaki, T., Clive, S., and Weir, C. J. (2013). Principles of dose finding studies in cancer: a comparison of trial designs. *Cancer chemotherapy and pharmacology*, 71(5):1107–1114.
- Lin, Y. and Shih, W. J. (2001). Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. *Biostatistics*, 2(2):203–215.
- Neuenschwander, B., Branson, M., and Gsponer, T. (2008). Critical aspects of the bayesian approach to phase i cancer trials. *Statistics in Medicine*, 27(13):2420–2439.
- O’Quigley, J., Pepe, M., and Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. *Biometrics*, pages 33–48.
- Storer, B. E. (1989). Design and analysis of phase i clinical trials. *Biometrics*, pages 925–937.
- Whitehead, J. and Williamson, D. (1998). Bayesian decision procedures based on logistic regression models for dose-finding studies. *Journal of Biopharmaceutical Statistics*, 8(3):445–467.